aweinsoff@channelchek.com, Author at Channelchek

Release – Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Posted on September 29, 2025September 29, 2025 by aweinsoff@channelchek.com

September 29, 2025 7:00am EDT Download as PDF

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND

TNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, providing the potential for a Priority Review Voucher upon approval

Magnesium-potentiated intranasal oxytocin formulation designed to reduce dose-related inconsistencies in receptor activity

CHATHAM, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated commercial-stage biotechnology company with innovative marketed products and a pipeline of development candidates, today announced plans to progress its TNX-2900 program for the treatment of Prader-Willi syndrome (PWS) into a Phase 2 clinical trial. TNX-2900 is a proprietary magnesium-potentiated intranasal oxytocin formulation designed to improve receptor binding and decrease dose-related inconsistencies in receptor activity. The program has received both Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA), which would make Tonix eligible for a transferable Priority Review Voucher, upon approval. The FDA has cleared the Investigational New Drug (IND) application for TNX-2900 to progress into Phase 2 development.

“We are pleased to advance TNX-2900 into a Phase 2 trial for PWS, a condition with unmet needs for new medicines with activity and tolerability,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Families caring for children with PWS face significant challenges and burdens. Among them is hyperphagia which drives persistent food-seeking behaviors that require constant supervision and often result in obesity and serious medical complications. With an average life expectancy of less than 30 years, treatment of PWS remains an urgent and unmet need. By addressing limitations of traditional oxytocin delivery, we believe TNX-2900 has the potential to become an FDA-approved therapy targeting the oxytocin receptor in PWS and provide meaningful benefit for patients and families living with this rare disorder.”

Tonix plans to conduct a Phase 2 randomized, double-blind, placebo-controlled, parallel-design study to evaluate the safety, tolerability, and efficacy of TNX-2900 in male and female participants with PWS, ages 8 to 17.5 years. Eligible participants will be randomized to receive 12-weeks of treatment with TNX-2900 at one of three dose levels, or placebo, in a 1:1:1:1 ratio. The primary efficacy endpoint will be the change from baseline in the validated Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a widely used measure of hyperphagia severity in PWS. Secondary objectives will include assessments of behavior, caregiver burden, and quality of life measures, as well as safety and tolerability outcomes.

Prader-Willi syndrome (PWS) is a rare genetic disorder and the leading cause of life-threatening childhood obesity, affecting about 1 in 10,000 to 1 in 30,000 births. Infants often present with poor muscle tone and feeding difficulties, while children and adolescents develop hyperphagia, behavioral challenges, and severe obesity and metabolic disease. Current interventions are difficult to sustain and often inadequate.

Research suggests PWS is associated with a functional deficiency of oxytocin, a neuropeptide that regulates satiety and feeding behaviors through the oxytocin receptor. Oxytocin treatment addresses several key features of PWS expressed in the MAGEL2 (MAGE-like 2) knock-out mouse.¹ Intranasal oxytocin therapy has shown benefits in infants with PWS.² Carbetocin has a different spectrum of activity on oxytocin and vasopressin receptors than oxytocin and carbetocin has not been tested to our knowledge in the MAGEL2 knock-out mouse.³ Oxytocin has dose-related inconsistencies in receptor activity that have been described as “high-dose suppression” or an “inverted “U” dose response.⁴ TNX-2900 is formulated with magnesium to further enhance oxytocin receptor binding and signaling, with the goal of providing more consistent and selective receptor activation while minimizing off-target vasopressin effects. In vitro and in vivo in animals Mg⁺⁺– containing formulations reduce these inconsistencies.⁴

About Prader-Willi Syndrome (PWS)

PWS is recognized as the most common genetic cause of life-threatening childhood obesity and affects males and females with equal frequency and all races and ethnicities. PWS results from the absence of expression of a group of genes, specifically related to the MAGE (melanoma antigen) gene family on the Prader–Willi critical region (15q11–q13) on the paternally acquired chromosome. The hallmarks of PWS are lack of suckling in newborns and, in children and adolescents, severe hyperphagia – an overriding physiological drive to eat, leading to severe obesity and other complications associated with significant mortality. A systematic review of the morbidity and mortality as a consequence of hyperphagia in PWS found that the average age of death in PWS was 22.1 years.⁵ Given the serious or life-threatening manifestations of these conditions, there is a critical need for effective treatments to decrease morbidity and mortality, improve quality of life, and increase life expectancy in people with PWS. Oxytocin has potent effects in correcting behavioral characteristics of the MAGEL2 knock-out mouse model for PWS and autism. ¹^,⁶^,7 Six clinical trials have investigated intranasal oxytocin as a treatment in pediatric patients with PWS. Four clinical studies showed evidence for improvement in PWS-related behaviors/symptoms/^2,8¹⁰ Three of these clinical studies reported evidence for improvement in hyperphagia^8-10 and one showed an improvement in sucking in infants.²

Schaller F, et al. Hum Mol Genet. 2010. 19:4895-4905.
Tauber M, et al. Pediatrics. 2017. 139(2):e20162976.
Meyerowitz JG, et al. Nat Struct Mol Biol. 2022 29(3):274-281.
Bharadwaj VN, et al. Pharmaceutics. 2022 14(5):1105.
Bellis SA, et al. Eur J Med Genet. 2022. 65(1):104379.
Bertoni A, et al. Mol Psychiatry. 2021. 26(12):7582-7595.
Meziane H, et al. Biol Psychiatry. 2015. 78: 85-94.
Kuppens RJ, et al. Clin Endocrinol. 2016. 85:979-987.
Miller JL et al. Am J Med Genet A. 2017. 173:1243-1250.
Damen L, et al. Clin Endocrinol. 2020. 94:774-785.

About TNX-2900 and Tonix’s Potentiated Oxytocin Platform

TNX-2900 is based on Tonix’s patented intranasal Mg²⁺-potentiated oxytocin formulation intended for use by children and adolescents. This formulation is believed to enhance the potency of oxytocin as well as increase specificity for oxytocin receptors relative to vasopressin receptors, potentially reducing unwanted side effects from activating vasopressin receptors. In collaboration with academic investigators, Tonix is also testing a different intranasal formulation, designated TNX-1900 for adolescent obesity, binge eating disorder, bone health in autism, and social anxiety disorder. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. Oxytocin is believed to be more than 600 million years old and is present in vertebrates including mammals, birds, reptiles, amphibians, and fish. It was initially approved by the U.S. Food and Drug Administration as Pitocin®, an intravenous infusion or intramuscular injection drug, for use in pregnant women to induce labor and control postpartum bleeding or hemorrhage. An intranasal formulation of oxytocin is marketed in some European countries to assist in breast milk production as Syntocinon® (oxytocin nasal 40 international units/ml).

Tonix Pharmaceuticals Holding Corp.*

Tonix Pharmaceuticals is a commercial-stage, fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix recently received FDA approval for Tonmya^TM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology and infectious diseases. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contact
Ray Jordan
Putnam Insights
ray@putnaminsights.com

INDICATION

TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS

TONMYA is contraindicated:

In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.

With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.

During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS

Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.

Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.

Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information.

To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: Tonix Pharmaceuticals Holding Corp.

Released September 29, 2025

Release – MustGrow Announces Grant of RSUs and DSUs

Posted on September 26, 2025September 26, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MGROF

SASKATOON, Saskatchewan, Canada, September 26, 2025 – MustGrow Biologics Corp. (TSXV: MGRO) (OTC: MGROF) (FRA: 0C0) (the “Company” or “MustGrow”) today announced that the board of directors of the Company authorized and approved the grant of a total of1,660,315 deferred share units (“DSUs”) and restricted share units (“RSUs”) to certain directors, officers, and consultants of the Company, effective September 25, 2025. This grants of DSUs and RSUs are made pursuant to the Company’s Omnibus Equity Incentive Plan (the “Plan”).

The DSUs will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable. On settlement, each DSU will entitle the holder to recive to receive one common share in the capital of the Company or a cash payment equivalent thereof at the discretion of the Company.

———

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 58.9 million common shares issued and outstanding and 69.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson

Director & CEO

Phone: +1-306-668-2652

info@mustgrow.ca

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

Release – Snail Games Announces Participation in the 2025 Steam Autumn Sale Lowering Cost Entry For ARK: Survival Ascended, Bellwright, and Indie Portfolio

Posted on September 26, 2025September 26, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SNAL

September 26, 2025 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., Sept. 26, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced its participation in this year’s Steam Autumn Sale, starting from September 29, 2025 through October 6, 2025. By featuring flagship titles, early access projects, and indie publishing partnerships, Snail aims to leverage this event as an opportunity to showcase portfolio depth, increase visibility, and potentially broaden its player base across multiple market segments.

Featured Discounts and Content Highlights:

ARK: Survival Ascended – 50% Off – Jump into the ultimate dinosaur survival adventure at 50% off and experience ARK like never before.
Bellwright – 20% Off – With over 1 million Steam wishlists, Bellwright remains in early access and may benefit from the visibility generated through seasonal events during its path to 1.0.
West Hunt – 50% Off – A social deduction party game that has developed its audience through visibility among multiplayer and streaming communities.
Survivor Mercs – 38% Off – An early access roguelite extraction shooter, where Snail anticipates that additional exposure during the sale may support community growth in advance of its 1.0 release.
Robots at Midnight – 30% Off – Designed as an accessible entry point into soulslike gameplay, the title combines immersive exploration, fast-paced combat, and a striking retro-futuristic setting.
Zombie Rollerz: The Last Ship – 19% Off – Stands out in the crowded roguelite and bullet heaven space by fusing tower defense strategy with bullet-dodging chaos, bringing a fresh twist to genre conventions through hybrid innovation.

Snail views seasonal promotions as a key element of its broader publishing strategy. During the recent Annual Steam Publisher Sale Event in June, significant discounts on many of its titles helped drive in-game engagement and sustained momentum throughout the month. Following the sale, ARK: Survival Evolved experienced a notable resurgence in both player engagement and sales, with over 3.8x total units sold, average daily sales increasing by 3,022% compared to prior months in 2025 and concurrent players peaking at 65,885 during the recent Steam Publisher Sale. These seasonal promotional events are designed to lower barriers to entry, making it easier for new players to explore established franchises while also drawing attention to early access projects still in active development. By participating in the Steam Autumn Sale, the Company aims to continue driving engagement for its established games while increasing exposure for indie and up-and-coming titles. This multifaceted approach has the potential to both diversify Snail’s player base and strengthen long-term engagement across its portfolio.

For creators interested in collaborative opportunities please reach out to creatordirect@noiz.gg

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and in our public filings with the SEC and include, but are not limited to, statements regarding the possibility that these seasonal promotions will reduce barriers to entry and our multifaceted approach has the potential to both diversify Snail’s player base and strengthen long-term engagement across out portfolio. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company’s Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

Release – Kratos to Showcase Advanced CCAs, UAS, and Defense Technologies at Miramar Air Show

Posted on September 25, 2025September 25, 2025 by aweinsoff@channelchek.com

Research News and Market Data on KTOS

September 25, 2025

PDF Version

Kratos Latest Weapons-Configured Valkyrie will be On-Site

Kratos MAKO Tactical Jet Drone, the First CCA to Demonstrate Manned-Unmanned Teaming in 2015, also to be Displayed

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets and an industry-leading provider of high-performance, jet-powered unmanned aerial systems, will display tactical and target unmanned jet drones, including the latest weapons-configured Valkyrie, at the upcoming Marine Corps Air Station Miramar Air Show September 26-28. Kratos’ tactical family of unmanned jet drones is designed for a range of military operations, including strike, ISR (intelligence, surveillance, and reconnaissance), RF (radio frequency), and communications. This lineup features the latest advancements, including the XQ-58 Valkyrie, UTAP-22 Mako, Tactical Firejet, and BQM-177 target system.

The Miramar Air Show invites both domestic and international visitors to explore full-scale Kratos tactical and target aircraft systems on display. These innovative systems exemplify the future of uncrewed air technology, providing proven and affordable solutions for mass production, deployment, and military engagement. Kratos’ unique approach aligns seamlessly with the Department of Defense’s latest technology initiatives and affordability strategies, enabling systems that can operate effectively from even the most remote locations worldwide.

The XQ-58 Valkyrie is a Collaborative Combat Aircraft (CCA)/ Autonomous Collaborative Platform (ACP) designed to operate with Joint and Allied Forces. Flying since 2019, the XQ-58 continues to pioneer tactical unmanned aerial system (UAS) technology and collaborative manned-unmanned capability.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/31ba6327-2f29-4591-857a-db61e1bd11db

Steve Fendley, President of Kratos Unmanned Systems Division, said, “We are proud to showcase our latest drone technologies at Miramar, offering attendees a unique opportunity to see these systems in person. Kratos is a recognized leader in unmanned systems, delivering affordable, high-performance aerial platforms like the XQ-58 Valkyrie that support a wide range of national security missions with speed, agility, and innovation. The Miramar Air Show is the ideal venue to highlight Kratos’ game changing systems that represent the future.”

Eric DeMarco, President and CEO of Kratos, said, “We are once again honored to be able to display Kratos’ affordable, leading technology hardware and systems at the Miramar Air Show with our partner, the United States Marine Corps. The Marines are a demonstrated-technology innovation leader, including Kratos’ UTAP 22 Mako, a CCA that began flying manned-unmanned teaming with USMC Harrier manned jet fighters in 2015, through today with Kratos’ Valkyrie flying with USMC F-35s. Kratos will continue to work closely with the Marines, including with certain of our most recent Drone related systems and capabilities.”

Kratos’ Tactical Firejet is designed to affordably meet requirements for fast ingress and egress of tactically denied battle spaces with the ability to deliver significant payloads over long ranges at high speed.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0bc3f8e4-e090-479f-9392-7d426986a291

Located in Hangar Three, visitors to Kratos’ display can also learn more about the Spartan Line of turbojet engines, showcasing unique capabilities for expendable engine applications, such as unmanned aerial systems and tactical missiles. Additionally, Kratos’ display will feature Elroy Air’s Chaparral, a hybrid-electric autonomous vertical takeoff-and-landing (VTOL) cargo drone, of which Kratos was recently announced as Elroy Air’s exclusive U.S. manufacturing partner.

Elroy Air’s Chaparral, of which Kratos is the exclusive U.S. manufacturer, is a hybrid-electric Vertical Take-Off and Landing cargo drone designed to autonomously transport 300 pounds of cargo over distances of 300 miles. Engineered for quick turnaround, efficiency, and safety, the Chaparral enables secure, uncrewed cargo delivery at a fraction of the capital and operational cost of piloted helicopters while eliminating risk to personnel in contested or high-risk logistics environments.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c93d5613-88c3-419b-9205-f0d4d7e46dac

The Kratos Mako is a high-speed, highly maneuverable unmanned aerial system (UAS) with open mission-system flexibility and ample payload capacity to make it an affordable and highly effective solution.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae73015-1771-4a63-912e-020364c1fa34

Miramar Air Show attendees will have the opportunity to engage with various static displays of advanced aircraft, providing insights into the latest innovations in aviation technology. Held at Marine Corps Air Station Miramar in San Diego, California, the show also features aerial performances and dynamic flight demonstrations with cutting-edge aircraft.

With advanced aerodynamic design, the BQM-177 is a formidable high-performance target for live-fire training scenarios, including sub-sonic, sea-skimming anti-ship cruise missile accurate threat emulation.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/30d20d69-c44a-43ed-aeee-ef4ad099306d

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to a variety of matters including, without limitation, Kratos’ expectations regarding the use of the proceeds from the public offering, the pipeline for opportunities, and Kratos’ success with respect to such opportunities, as well as other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements including, but not limited to: risks and uncertainties related to market conditions as well as general economic factors. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Release – MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

Posted on September 24, 2025September 24, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MAIA

September 24, 2025 8:01am EDT Download as PDF

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC)

CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced today that the National Institutes of Health (NIH) has awarded a $2.3 million grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC).

The grant is intended to support expenses related to the enrollment of U.S. patients who are resistant to chemo and immunotherapy. The NIH grant allocations will be distributed over three years from 2025-2027.

“We are thrilled to receive this prestigious NIH grant for the expansion of our Phase 2 trial. It’s a great honor to have the support of the National Institutes of Health as we seek to further validate the efficacy of our lead agent ateganosine and its potential to be a breakthrough treatment within the vastly underserved NSCLC market,” said CEO Vlad Vitoc, M.D. “With the clearance of FDA Investigational New Drug (IND) for THIO-101 in 2023, we can begin enrolling U.S. patients in the expansion phase of the trial immediately.”

“The NIH grant is a tremendous achievement and a testament to the dedication, collaboration, and hard work of everyone involved in the clinical development of ateganosine,” added Victor Zaporojan, M.D., MAIA’s senior medical director. “Ateganosine represents a potential solution for the significant unmet clinical need in third-line NSCLC, where no established standard of care exists and where the overall survival outcomes observed with ateganosine have not been achieved by other therapies. By enrolling patients in the United States, our trial will gain access to a substantially larger patient pool across multiple continents, further strengthening the impact and relevance of our study.”

In Parts A and B of THIO-101, median overall survival (OS) for the 22 patients in third-line treatment was 17.8 months as of June 30, 2025, with a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months. The first patient in the expansion of the trial was dosed in July 2025 in Taiwan.

Research referenced in this press release is supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA309843. The content is solely the responsibility of MAIA and does not necessarily represent the official views of the National Institutes of Health.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo^®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo^®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released September 24, 2025

Release – Kratos and GE Aerospace’s Small Engine Testing Gains Altitude

Posted on September 23, 2025September 23, 2025 by aweinsoff@channelchek.com

Research News and Market Data on KTOS

September 23, 2025

PDF Version

GEK800 Small Engine Designed to Power the Next Generation of Affordable Unmanned Aerial Systems and CCA-type Aircraft

AFRL, GE Aerospace, Kratos Defense, and Purdue Zucrow Labs Collaborating on Extremely Tight Testing Timeline

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, and GE Aerospace (NYSE: GE) announced that they have started altitude testing on its GEK800 small engine designed to power the next generation of affordable unmanned aerial systems and CCA-type aircraft. The testing began today at an altitude test facility at Purdue University’s Maurice J. Zucrow Laboratories.

“Altitude testing is the next milestone in demonstrating our commitment to delivering high-performance, affordable, jet engines to support our defense customers,” said Stacey Rock, President of Kratos Turbine Technologies. “Our team is uniquely positioned to bring these advanced designs into high-rate production to support the rising demand for propulsion systems for cruise missiles and CCA-type aircraft. The GEK800 has been designed and engineered up front, from conception, to be manufactured in large quantities at a low cost.”

“The GEK800 engine has performed well and exceeded our expectations in its ground testing to date,” said Mark Rettig, Vice President of Edison Works Advanced Programs at GE Aerospace. “During altitude testing, we will collect data on the engine’s performance in a range of altitudes to assess its operability in simulated real-world conditions.”

“We are thrilled that the propulsion test infrastructure of our new lab created the opportunity to test the new GEK800 engine,” said Scott Meyer, Managing Director of Zucrow Laboratories. “The cooperation and comradery between the GE and Kratos teams, and our students and staff at Zucrow Labs, has been amazingly productive and a pleasure to be a part of. We are excited to have a role in the development of this critical new capability for our nation.”

The GEK800 is an 800-lb jet engine that could potentially power unmanned aerial systems (UAS), collaborative combat aircraft (CCAs), and missiles. Initially developed and ground tested by Kratos over the course of a decade, Kratos and GE Aerospace began working together in 2023 to complete additional development efforts and testing on the engine and have completed more than 50 engine starts in ground testing at Kratos and GE Aerospace testing facilities.

The altitude testing will focus on an altitude window between 5,000-35,000 feet and is anticipated to be complete by the end of the year. GE Aerospace, Kratos, and Purdue University have been collaborating for the last few months on the engine testing, which will be the first engine to test at newly expanded ZL9 test facility at Zucrow Labs.

“The collaboration between AFRL, GE Aerospace, Kratos Defense, and Purdue Zucrow Labs on an extremely tight timeline is outstanding. While demonstrating engine technology is clearly significant, the successful development of rapid and affordable altitude test capability is a crucial element in delivering on our nation’s defense readiness,” said Chris Rawlings, Vice President, of Kratos Turbine Technologies Defense Programs.

In June, Kratos and GE Aerospace announced the signing of a formal teaming agreement to advance propulsion technologies for the next generation of affordable unmanned aerial systems and CCA-type aircraft. This collaboration strengthens the companies’ ongoing partnership and builds on last year’s Memorandum of Understanding (MOU) to advance the development and production of small, cost-effective engines for unmanned platforms. The new teaming agreement expands on that MOU and provides the framework for the two companies to develop, manufacture, test, and field the GEK800 engine.

Kratos brings more than 25 years of experience developing and producing small, affordable engines for UAS, drones, and missile platforms. GE Aerospace adds a century of expertise in propulsion technology and the ability to scale advanced designs into high-rate production —helping bridge the gap from prototype to deployment.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital, and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule, and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high, and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

About GE Aerospace
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 49,000 commercial and 29,000 military aircraft engines. With a global team of approximately 53,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow, and the future at www.geaerospace.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Media Contacts:
GE Aerospace: Deb Case Deborah.case@geaerospace.com +1-513-418-1644

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Release – Kratos to be Exclusive U.S. Manufacturer for the Elroy Air Chaparral VTOL Cargo Drone

Posted on September 23, 2025September 23, 2025 by aweinsoff@channelchek.com

Research News and Market Data on KTOS

September 23, 2025

PDF Version

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, today announced that Elroy Air, a leading developer of autonomous aerial cargo systems for middle-mile logistics and military resupply, has selected Kratos as Elroy Air’s exclusive U.S. manufacturing partner for the Chaparral in a new five-year strategic manufacturing agreement to accelerate expected high-volume production of the Chaparral hybrid-electric autonomous vertical takeoff-and-landing (VTOL) cargo drone.

Elroy Air’s Chaparral, shown here in flight, to be manufactured by Kratos

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b26d881-f3c8-4fb5-bee9-f28c41e9f5cb.

“Kratos is an established and trusted producer of military UAS and is unique in their manufacturing focus on affordability. Kratos has produced and delivered thousands of uncrewed aircraft, with a well-established and reliable supply chain for these systems. Their expanded production capabilities make them the ideal partner to bring Chaparral to market at scale,” said Elroy Air CEO Andrew Clare. “This partnership accelerates our ability to deliver Chaparral systems to the many customers waiting for them, across both defense and commercial markets.”

Kratos, a proven leader in the development and production of affordable, jet-powered composite unmanned aircraft for the U.S. Department of Defense, recently expanded its manufacturing capacity to support next-generation drone production. This new partnership leverages Kratos’ deep expertise and scaled infrastructure to put the Chaparral into high-volume production.

Eric DeMarco, President and CEO of Kratos, said, “Kratos is the recognized industry leader for rapid development, production, and delivery of affordable, leading technology unmanned aerial drone systems, which is a perfect fit with Elroy Air’s UAV roadmap, incredibly large forecasted addressable market and related future high volume production plans, including for the U.S. military. Kratos provides Elroy Air an immediate and unique competitive, customer differentiating, value-multiplier advantage, with Kratos’ up and running manufacturing facilities, qualified and executing supply chain and relevant past performance qualifications. Kratos’ partnership with Elroy Air is a recent example of Kratos delivering relevant products, not promises, power points and renditions, with expected tangible value creation for our stakeholders.”

“We are thrilled to partner with Elroy Air to produce their industry-leading drone for the dual-use market,” said Steve Fendley, President of Kratos Unmanned Systems Division. “Elroy Air’s market opportunity for Chaparral is already large and continuing to grow. With this growth, Kratos is ideally suited to transition the system to production. The Kratos team is the best in the world at establishing UAS production lines and optimizing affordability.”

Chaparral is designed to autonomously transport up to 300 pounds of cargo over 300 miles, affordably bridging critical logistics gaps for military resupply, disaster relief, and commercial express delivery. The vehicle’s unique hybrid-electric powertrain enables rapid refueling, extra power for recharging batteries and powering payloads in cruise flight, and longer-range cargo transport than similar-sized battery-electric aircraft.

Kratos will perform initial production of Chaparral at their Sacramento, California aircraft production facility and over time, transition to high-rate production at Kratos’ facilities in Oklahoma City. These efforts are expected to bring aerospace jobs to both regions and expand the current supply chain infrastructure that includes many other states across our nation. The first production Chaparral aircraft are planned to be built in 2026.

“Kratos’ proven ability to produce large, composite drones in high volumes makes them the perfect partner to help us scale production of the Chaparral,” said Dave Merrill, Elroy Air’s Founder and Executive Chairman. “Our customers are eager to expand their operations with our systems, and Kratos’ deep production expertise and track record will enable us to deliver robust, world-class Chaparral vehicles in high volumes.”

Kratos and Elroy Air will have their unmanned aircraft systems on display together at the upcoming Miramar Air Show held September 26-28 at the Marine Corps Air Station Miramar in San Diego, California.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding-edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit http://www.kratosdefense.com.

About Elroy Air
Elroy Air is developing industry-first autonomous aircraft systems and cutting-edge software to revolutionize express shipping. Deploying innovative hybrid-electric and autonomous vehicle technologies, their vertical-takeoff-and-landing (VTOL) aircraft transcend traditional airport limitations, unlocking new frontiers in commercial air cargo, humanitarian aid, and military logistics. From agile, low-risk resupply for troops, to dynamic disaster response and firefighting support, to warehouse-to-warehouse express parcel transport, Elroy Air’s technology reshapes logistics possibilities. With facilities in Byron California, Elroy Air is backed by premier venture capital firms including Diamondstream Partners, Catapult Ventures, Marlinspike Partners, Snowpoint Ventures, and Shield Capital. Strategic investment from industry giants like Lockheed Martin Ventures and support from visionary angel investors including early Uber executives drive the company’s mission to provide same-day shipping to every person on the planet. For more information, visit elroyair.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Elroy Air’s Chaparral, shown here in flight, to be manufactured by Kratos

Elroy Air’s Chaparral, shown here in flight, to be manufactured by Kratos

Source: Kratos Defense & Security Solutions, Inc.

Release – MariMed’s Betty’s Eddies Spreads Importance of Cancer Screening Education and Awareness through Partnership with Keep A Breast Foundation

Posted on September 23, 2025September 23, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MRMD

September 23, 2025 7:30am EDT Download as PDF

Third Annual Collaboration Coincides with Breast Cancer Awareness Month

NORWOOD, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) — Betty’s Eddies™ announced its third annual collaboration with the Keep A Breast Foundation (“KAB”), furthering its commitment to breast cancer awareness, early screening education, and community support. After years of hearing from patients and consumers who have used Betty’s Eddies to help cope with treatment-related ailments, the brand is continuing its mission to spotlight the power of cannabis alongside preventative health practices. Betty’s Eddies, the award-winning, all-natural cannabis fruit chews handcrafted for specific health and wellness effects, is produced and distributed by leading multi-state cannabis operator, MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD).

This year’s campaign once again features a limited-time pink package for the fan-favorite Ache Away Eddies fruit chews, available across Massachusetts, Maryland, Illinois, and Delaware. The packaging promotes the Keep A Breast app, a free resource on Apple and Google Play that educates users on self-checking, offers risk-reduction tips, and connects directly to medical professionals when needed. Ache Away Eddies, infused with CBD, CBC, and THC, plus turmeric, piperine, and vitamin E, may help ease inflammation and aid recovery.

To amplify awareness, Betty’s Eddies will also distribute a limited number of “Betty’s Loves Boobies” bracelets and t-shirts at select dispensaries and online, while supplies last. The brand will be donating $5 from the sale of every t-shirt to KAB in support of its mission.

“Over the past three years, our partnership with Betty’s Eddies has reached thousands of new people with life-saving education around early detection and screening,” said Shaney Jo Darden, Founder of the Keep A Breast Foundation. “As cannabis continues to show promise in easing the painful side effects of cancer treatment, Betty’s Eddies remains an ideal partner in helping us expand our impact.”

In addition to its partnership with KAB, Betty’s Eddies team members will participate in multiple Susan G. Komen More Than Pink Walks this October, showing support, raising awareness, and connecting directly with local communities in Maryland on Saturday, October 11, 2025, and in Massachusetts on Saturday, October 18, 2025. The Susan G. Komen Foundation focuses its work on patient navigation and advocacy, providing resources for breast cancer patients to understand the American medical system.

“Betty’s Eddies is deeply committed to promoting health and wellness and doing so in a fun, yet educational way,” said Sara Rosenfield, Brand Manager for Betty’s Eddies. “Our partnership with the Keep A Breast Foundation and our Breast Cancer Awareness Month campaign is a natural extension of that commitment. We’re proud to help educate the community about the importance of prioritizing their health and contribute to ridding the world of this horrible disease, while sharing the benefits cannabis can have in providing relief.”

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Release – The ODP Corporation to Be Acquired by Atlas Holdings in All-Cash Transaction

Posted on September 22, 2025September 22, 2025 by aweinsoff@channelchek.com

Research News and Market Data on ODP

PDF Version

The ODP Corporation Shareholders to Receive $28 Per Share in Cash, Representing a 34% Premium to Closing Stock Price on September 19, 2025

Transaction to Generate Significant Value for The ODP Corporation Shareholders

BOCA RATON, Fla. & GREENWICH, Conn.–(BUSINESS WIRE)–Sep. 22, 2025– The ODP Corporation (NASDAQ:ODP), a leading provider of products, services and technology solutions to businesses and consumers, today announced that it has entered into a definitive agreement to be acquired by an affiliate of Atlas Holdings, which owns and operates a global family of manufacturing and distribution businesses, for $28 per share in cash. The purchase price represents a premium of 34% to The ODP Corporation’s closing share price on September 19, 2025, valuing The ODP Corporation at approximately $1 billion. Upon completion of the transaction, The ODP Corporation will become a privately held company, and shares of common stock will no longer be listed on the NASDAQ stock exchange.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922099559/en/

“This transaction, fully supported by our Board, provides a substantial premium for The ODP Corporation’s shareholders and will improve the company’s position for the next phase of growth,” said Gerry P. Smith, Chief Executive Officer of The ODP Corporation. “Atlas brings an understanding of our industry, along with the operational expertise, resources and track record of supporting its companies that will fast forward our B2B growth initiatives and strengthen our position as a trusted partner to our customers. Atlas’ commitment demonstrates their confidence in our future and the strong momentum we’ve achieved through our focus on operational excellence and disciplined execution. We’re excited about our path for the future.”

“Atlas has a long history of transitioning public companies into successful private enterprises and we are uniquely positioned to do just that with The ODP Corporation – an iconic American company,” said Atlas Managing Partner Michael Sher. “Atlas operates like a diversified holding company, and we have a proven record of delivering the human and financial capital necessary to create long-term value in our businesses. The ODP Corporation’s leadership has already taken several steps to mitigate the challenging retail environment, and we are the right partners to support The ODP Corporation’s continued evolution in its next chapter. We look forward to completing this transaction which will provide a positive outcome for The ODP Corporation’s associates, customers, suppliers and shareholders.”

The Board of Directors of The ODP Corporation unanimously approved the transaction, which is expected to be completed by the end of 2025. The transaction is subject to customary closing conditions, including regulatory approvals and approval by The ODP Corporation shareholders.

J.P. Morgan Securities LLC is serving as exclusive financial advisor and Simpson Thacher & Bartlett LLP is serving as legal advisor to The ODP Corporation. Lazard is serving as financial advisor and Willkie Farr & Gallagher LLP is serving as legal advisor to Atlas Holdings.

About The ODP Corporation

The ODP Corporation (NASDAQ:ODP) is a leading provider of products, services, and technology solutions through an integrated business-to-business (B2B) distribution platform and omnichannel presence, which includes world-class supply chain and distribution operations, dedicated sales professionals, online presence and a network of Office Depot and OfficeMax retail stores. Through its operating companies ODP Business Solutions, LLC; Office Depot, LLC; and Veyer, LLC, The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.

About Atlas Holdings

Headquartered in Greenwich, Connecticut and founded in 2002, Atlas and its affiliates own and operate 29 companies which employ more than 60,000 associates across 375 facilities worldwide. Atlas operates in sectors such as automotive supply, building materials, capital equipment, construction services, food manufacturing and distribution, metals processing, packaging, paper, power generation, printing, pulp, supply chain management and wood products. Atlas’ companies together generate more than $20 billion in revenues annually.

Forward Looking Statements

The foregoing contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “hope,” “hopeful,” “likely,” “may,” “optimistic,” “possible,” “potential,” “preliminary,” “project,” “should,” “will,” “would” or the negative or plural of these words or similar expressions or variations. Forward-looking statements are made based upon management’s current expectations and beliefs and are not guarantees of future performance. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. These factors include, among others: (i) the completion of the proposed transaction on the anticipated terms and timing; (ii) the satisfaction of other conditions to the completion of the proposed transaction, including obtaining required shareholder and regulatory approvals; (iii) the risk that the Company’s stock price may fluctuate during the pendency of the proposed transaction and may decline if the proposed transaction is not completed; (iv) potential litigation relating to the proposed transaction that could be instituted against the Company or its directors, managers or officers, including the effects of any outcomes related thereto; (v) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, including during the pendency of the proposed transaction; (vi) the ability of the Company to retain and hire key personnel; (vii) the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction and integration matters; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (ix) legislative, regulatory and economic developments; (x) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect the Company’s financial performance; (xi) certain restrictions during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; (xii) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, outbreaks of war or hostilities or global pandemics, as well as management’s response to any of the aforementioned factors; (xiii) the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) unexpected costs, liabilities or delays associated with the transaction; (xv) the response of competitors to the transaction; (xvi) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction, including in circumstances requiring the Company to pay a termination fee; and (xvii) other risks set forth under the heading “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 28, 2024 and in our subsequent filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Additional Information and Where to Find It

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed acquisition of The ODP Corporation by ACR Ocean Resources LLC. In connection with this proposed acquisition, The ODP Corporation plans to file one or more proxy statements or other documents with the SEC. This communication is not a substitute for any proxy statement or other document that The ODP Corporation may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF THE ODP CORPORATION ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of The ODP Corporation. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by The ODP Corporation through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by The ODP Corporation will be available free of charge on The ODP Corporation’s internet website at theodpcorp.com or upon written request to: The ODP Corporation, Investor Relations, 6600 North Military Trail Boca Raton, FL 33496 or by email to investor.relations@theodpcorp.com.

Participants in Solicitation

The ODP Corporation, its directors and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of The ODP Corporation is set forth in its proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on March 20, 2025. To the extent that holdings of The ODP Corporation’s securities by its directors or executive officers have changed since the amounts set forth in The ODP Corporation’s proxy statement for its 2025 annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC.

Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

The ODP Corporation
Investor Relations
6600 North Military Trail Boca Raton, FL 33496
investor.relations@theodpcorp.com
theodpcorp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250922099559/en/

For The ODP Corporation:

Tim Perrott
Investor Relations
561-438-4629
Tim.Perrott@theodpcorp.com

H/Advisors Abernathy
Dan Scorpio / James Bourne
(646) 899-8118 / (213) 212-1134
dan.scorpio@h-advisors.global / james.bourne@h-advisors.global

For Atlas Holdings:

Longacre Square Partners
Kate Sylvester
atlasholdings@longacresquare.com

Source: The ODP Corporation

Release – V2X Completes Acquisition of QinetiQ U.S. Intelligence Business, Expanding National Security Capabilities

Posted on September 22, 2025September 22, 2025 by aweinsoff@channelchek.com

Research News and Market Data on VVX

September 22, 2025

Download(opens in new window)

RESTON, Va., Sept 22, 2025 /PRNewswire/ — V2X, Inc. (NYSE: VVX) today announced the successful completion of its acquisition of QinetiQ’s U.S. Intelligence business, a provider of data engineering, intelligence mission support, and cyber solutions for the Intelligence Community.

The transaction, valued at approximately $24 million net of estimated tax benefits, adds new capabilities and expands V2X’s access to critical national security programs. Approximately 70 professionals with deep expertise in intelligence and cyber operations will join V2X as part of the acquisition.

“This acquisition enhances our position in the Intelligence Community and strengthens our ability to deliver data-enabled mission solutions across all domains,” said Jeremy C. Wensinger, President and Chief Executive Officer of V2X. “We are pleased to welcome this talented team and look forward to delivering greater value to our customers and shareholders.”

Integration of the QinetiQ Intelligence business into V2X’s national security portfolio is already underway and will continue over the coming months.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-completes-acquisition-of-qinetiq-us-intelligence-business-expanding-national-security-capabilities-302562302.html

SOURCE V2X, Inc.

Release – The Oncology Institute Achieves $1.1 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 2 through its California Professional Corporation

Posted on September 22, 2025September 22, 2025 by aweinsoff@channelchek.com

Research News and Market Data on TOI

Sep 22, 2025

PDF Version

Practice earns maximum quality points on avoidable ED visits and admissions, saving more than $3,500 per episode

CERRITOS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, achieved $1.1 million in Medicare savings during Performance Period 2 of the Centers for Medicare & Medicaid Services’ Enhancing Oncology Model (EOM) through its California professional corporation, with savings equating to more than $3,500 per patient episode. TOI earned the maximum score on avoidable emergency department visits and hospital admissions. Results were driven by our High Value Cancer Care program conducted by Health Care Coaches and 24/7 symptom management support that helped patients stay on treatment and out of the hospital.

EOM is a voluntary total-cost-of-care model created by the CMS Innovation Center to advance high-quality, person-centered, and equitable cancer care for Medicare Fee-for-Service beneficiaries.

“These results again prove that our proactive navigation and real-time symptom management reduce unnecessary hospital visits and keep patients on treatment,” said Dr. Yale D. Podnos, Chief Medical Officer and President of Practice. “Patients across all our markets have access to these proven best practices to ensure each patient receives the right care at the right time.”

“This performance reinforces TOI’s leadership in value-based oncology,” said Dan Virnich, Chief Executive Officer. “By delivering measurable savings while improving quality, we continue to demonstrate that high-value cancer care is both clinically superior and financially sustainable.”

TOI’s success in EOM builds on its track record in CMS’s prior Oncology Care Model, where the organization exceeded quality standards and generated multi-million-dollar savings for Medicare.

About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors
ICR Healthcare
TOI@icrhealthcare.com

Release – Kratos Defense & Security Solutions to Join S&P MidCap 400 Index

Posted on September 22, 2025September 22, 2025 by aweinsoff@channelchek.com

Research News and Market Data on KTOS

September 22, 2025

PDF Version

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, announced today that it will be added to the S&P MidCap 400 Index, transitioning from the S&P SmallCap 600 Index.

The move reflects Kratos’ continued growth, performance, and market recognition as the company scales its leadership in unmanned systems, hypersonics, space, propulsion, and other national security solutions. Placement in the MidCap 400 highlights Kratos’ trajectory as it executes on key programs and expands its role within the U.S. defense industrial base.

“We are honored to be recognized through our inclusion in the S&P MidCap 400, a milestone that reflects both our financial growth and the confidence in Kratos’ strategy,” said Eric DeMarco, President and CEO of Kratos. “This achievement underscores the hard work of our employees, the trust of our customers and partners, and the company’s commitment to delivering affordable, high-performance systems that support U.S. and allied national security.”

The S&P MidCap 400 Index measures the performance of mid-sized companies across diverse industries in the United States and is widely regarded as a leading benchmark for institutional and retail investors. Companies in the index are selected for their balance of size, liquidity, and representation of the U.S. mid-cap market, making inclusion an important marker of corporate growth and visibility.

Kratos remains focused on delivering cutting-edge defense technologies at an accelerated pace, leveraging its commercial approach to drive affordability and agility in support of the U.S. Department of Defense and allied partners worldwide. For more information about Kratos and its industry-leading solutions, visit www.KratosDefense.com.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, advanced vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Release – Xcel Brands Appoints Olin Lancaster as Chief Revenue Officer

Posted on September 19, 2025September 19, 2025 by aweinsoff@channelchek.com

Research News and Market Data on XELB

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a media and consumer products company known for building influential, creator-led brands, today announced the appointment of Olin C. Lancaster as Chief Revenue Officer. With more than three decades of leadership in global consumer brands, Lancaster brings a proven track record of driving revenue growth, brand building, and operational excellence.

Lancaster’s career spans senior leadership roles at Kenneth Cole, DKNY, Global Brands Group, Ralph Lauren, and most recently Meridian Brands, where he served as CEO. At Ralph Lauren, he oversaw the North American wholesale business which experienced significant growth and profit expansion during his tenure. At Meridian, he guided the company through a successful rebrand and restructuring, significantly strengthening profitability and operational performance.

“Olin is one of the most respected leaders in our industry with an unmatched ability to scale brands and drive profitability,” said Robert W. D’Loren, Chairman and CEO of Xcel Brands. “His extensive experience across wholesale, retail, and brand operations makes him a powerful addition to our leadership team as we continue to expand our portfolio of creator-led and digitally driven businesses.”

“I am truly excited to join XCEL and work closely with Bob D’Loren and the team. Activating and monetizing brands today is difficult and expensive. XCEL is as much a media company as it is a brand management and licensing company, and I believe that is the real unlock in our ability to attract and create value with our partners, both on the founder/creative side and with our operators,” said Olin Lancaster.

Originally from Dallas, Texas, Lancaster is a graduate of Southern Methodist University, where he earned a BA in History with minors in Business and Economics. Lancaster also serves on the board of Mizzen + Main and is an active supporter of The Meadows Foundation in Dallas.

For more information, please visit www.xcelbrands.com

About Xcel Brands
Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel owns the Halston, Judith Ripka, and C. Wonder brands, as well as the co-branded collaboration brands Towerhill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford, and a brand in development with Coco Rocha and also holds noncontrolling interests or long-term license agreements in the Isaac Mizrahi brand, Orme Live, and Mesa Mia by Jenny Martinez. Xcel also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers shop. The company’s brands have generated in excess of $5 billion in retail sales via livestreaming in interactive television and digital channels alone, and over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches in excess of 43 million social media followers with broadcast reach into 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.

For further information please contact:
Seth Burroughs
Xcel Brands
sburroughs@xcelbrands.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/71b1e75c-9e66-4e2b-ac0d-d15f6a52da53

Source: Xcel Brands, Inc